The Regulatory Mix

On this episode of The Regulatory Mix, we break down the new PIC/S Recommendation PI 058-1, Interpretation of the Most Important Changes in the Annex 1 on the Manufacture of Sterile Products (2022).The document entered into force on October 28, 2026 and was developed jointly through the PIC/S, EMA, and WHO Annex 1 implementation group. Importantly, PI 058-1 does not create new GMP requirements. Instead, it provides a harmonized Q&A interpretation of how inspectors are expected to apply the revised Annex 1 during sterile manufacturing inspections.The episode focuses on the practical issues sterile manufacturers are most likely to feel during inspection: how the Contamination Control Strategy should function as a living system rather than a standalone document, expectations for PUPSIT, the limitations of VHP as a sterilization method, airflow visualization and first-air protection, WFI monitoring, APS frequency and failure response, personnel qualification, single-use systems, and environmental monitoring.One of the most important themes is that Annex 1 compliance is increasingly about demonstrating how controls work together. A firm may have strong procedures for gowning, environmental monitoring, disinfection, utilities, APS, and equipment qualification, but inspectors will expect those controls to be connected through the CCS and supported by actual performance data.The document also provides useful clarification in areas that have generated debate since the revised Annex 1 became effective, including cleanroom transfer practices, alternative airflow velocities, disinfectant rotation, cold WFI systems, supplier reliance for single-use systems, and what happens after a failed APS.The takeaway: PI 058-1 gives industry a much clearer view of how Annex 1 will be interpreted at the inspection level. For sterile manufacturers, this is a good document to use for a targeted gap assessment before the inspector arrives.PIC/S PI 058-1:https://picscheme.org/docview/11495PIC/S Announcement:https://picscheme.org/en/news/150/adoption-and-entry-into-force-of-pics-recommendation-pi-058Disclosure:The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.

On this episode of The Regulatory Mix, we break down FDA’s updated Concept of Operations for Facility Evaluation and Inspection of Human Drugs and answer a deceptively simple question:After the investigator leaves, who is actually reviewing my inspection?The answer depends on the type of inspection and what FDA is evaluating.The updated ConOps lays out how responsibilities are divided across Preapproval, Postapproval, Surveillance, and For-Cause inspections. OII generally leads the field inspection, while offices within CDER, including OPQ, OPMA, OQS, and OMQ, take on different roles in facility risk assessment, application decisions, inspection classification, and compliance follow-up.For a preapproval inspection, OPMA may be heavily involved because the question is whether the facility can support approval of a pending application. During routine surveillance, OQS helps drive risk-based site selection and develops the quality intelligence used before the inspection, while OMQ becomes particularly important when findings move toward VAI or OAI classification and potential compliance action.The document also shows how FDA is increasingly blending traditional inspections with Remote Regulatory Assessments, Section 704(a)(4) records requests, Remote Interactive Evaluations, and Mutual Recognition Agreement inspection reports. The inspection is only one piece of a much larger facility evaluation process.That means your Form FDA 483 response may ultimately be evaluated alongside application commitments, prior inspection history, complaints, recalls, quality intelligence, remote records, and information from other regulatory authorities.The takeaway: the investigator may conduct the inspection, but the regulatory decision can involve several different offices after the inspection is over. Understanding who owns that next decision helps explain why inspection responses need to address more than just the individual observations on the Form FDA 483.Source:FDA – Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operationshttps://www.fda.gov/media/107225/download?attachmentDisclosure:The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice.Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.

On this episode of The Regulatory Mix, the discussion focuses on a major new policy shift affecting peptide compounding under Section 503A.HHS has announced an interim enforcement discretion policy allowing certain state-licensed pharmacies, federal facilities, and licensed physicians to compound drug products using six specified peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, provided the policy’s conditions are met.The significance is not that these peptides are now FDA-approved or formally added to the 503A Bulks List. Rather, HHS is creating an interim pathway while formal rulemaking continues. That makes this a meaningful change for compounders, prescribers, and patients who have been operating in a much more restrictive environment around these substances.The policy also comes with significant conditions around sourcing, analytical testing, labeling, adverse event reporting, patient-specific prescriptions, route of administration, and product configuration. In other words, this is not a blanket green light. It is a tightly conditioned enforcement discretion framework.The bigger story is what this signals about the future of peptide compounding. HHS is clearly willing to create a controlled pathway for certain high-interest peptides while formal regulatory processes catch up, but the quality and documentation expectations remain substantial.The takeaway: this may open the door for peptide compounding, but it does not remove the need for strong sourcing controls, validated testing, patient-specific prescribing, and disciplined quality oversight.Sources:HHS Federal Register Public Inspection Notice:https://public-inspection.federalregister.gov/2026-22192.pdfHHS 503A Peptide Enforcement Discretion Policy — Appendix B:https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdfDisclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.

On this episode of The Regulatory Mix, the discussion goes inside one of the most visual, and often misunderstood, elements of sterile manufacturing: the airflow visualization study, better known as the smoke study.At its core, a smoke study demonstrates that HEPA-filtered first air continues to protect exposed sterile product, components, and critical surfaces during actual operations. That means evaluating airflow not only at rest, but dynamically, with equipment running, operators in position, and representative interventions taking place.The episode explores what good airflow visualization should show: continuous unidirectional airflow over and away from critical areas, no problematic eddies or stagnant zones, and no operator or equipment movement that redirects lower-quality air toward exposed sterile surfaces. A system that looks perfect when empty can behave very differently once real operations begin.We also get into the practical side of execution. Fog generation method, manifold design, camera placement, lighting, tracer density, equipment positioning, and even how the fog is introduced can affect what the video appears to show. ASTM E3379-25 provides a modern framework for critical airflow visualization and reinforces that the goal is to demonstrate protection of the critical zone under representative conditions.EU GMP Annex 1 has further elevated airflow visualization by linking it to the broader Contamination Control Strategy (CCS). Smoke studies should not exist as isolated qualification videos. Their findings should influence intervention design, equipment placement, environmental monitoring locations, operator practices, and training.FDA’s aseptic processing guidance similarly treats airflow visualization as an important tool for demonstrating appropriate airflow patterns in critical areas. The expectation is not simply to create a dramatic cloud of smoke, but to produce meaningful evidence that the process environment protects sterile product.The takeaway is simple: a smoke study is not just a qualification video. It is a real-world test of facility design, equipment integration, operator behavior, intervention strategy, and contamination control.And once you spend time on the execution side, one thing becomes clear: getting the airflow right is only half the battle. Getting the camera angle, fog delivery, interventions, lighting, and documentation right enough to prove it can be an entirely different challenge.References & Links:ASTM E3379-25 – Standard Guide for Critical Airflow Visualizationhttps://store.astm.org/e3379-25.htmlEU GMP Annex 1 – Manufacture of Sterile Medicinal Productshttps://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_enFDA – Sterile Drug Products Produced by Aseptic Processinghttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practiceWHO Technical Report Series 961https://www.who.int/publications/i/item/9789241209618ISO 14644-3:2019 – Cleanrooms and Associated Controlled Environments — Test Methodshttps://www.iso.org/standard/60598.htmlUSP <797> – Pharmaceutical Compounding—Sterile Preparationshttps://doi.usp.org/USPNF/USPNF_M99925_09_01.htmlDisclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on FDA’s updated 2026 guidance for biosimilar and interchangeable biological products and what it means for development strategy, product design, pediatric requirements, and postapproval manufacturing.FDA’s latest Q&A reinforces an important principle: a biosimilar does not have to be an exact physical copy of its reference product. Sponsors may use different formulations, container closure systems, or delivery devices, and they may seek approval for fewer indications, presentations, or routes than the reference product. But that flexibility has clear statutory limits. A 351(k) applicant cannot use the abbreviated pathway to introduce a different strength, dosage form, route of administration, or an indication that has never been approved for the reference product.That creates some interesting strategic opportunities. A biosimilar may, for example, move from a vial presentation to a prefilled syringe or auto-injector if the sponsor can support the change with appropriate performance, stability, extractables and leachables, and human factors data. At the same time, converting a lyophilized “for injection” product into a ready-to-use “injection” crosses the statutory line because FDA considers those different dosage forms. The episode also explores a less obvious area: pediatric requirements. Non-interchangeable biosimilars can trigger PREA obligations because they are treated as having a new active ingredient for PREA purposes, but FDA does not interpret that to mean biosimilar sponsors must develop pediatric indications, strengths, or dosage forms that the reference product itself does not have. The 351(k) pathway effectively limits the scope of those pediatric obligations.Postapproval manufacturing is another major theme. Once a biosimilar is licensed, manufacturers do not need to continue purchasing the reference product indefinitely every time they make a manufacturing change. FDA’s postapproval guidance allows routine comparability assessments to rely primarily on side-by-side evaluation of pre-change and post-change material, supported by a well-qualified in-house reference standard and ICH Q5E principles.That is a meaningful lifecycle advantage. Changes such as scale-up, facility transfers, purification modifications, or new presentations can be managed through the appropriate PAS, CBE, or Annual Report pathway based on risk. In some cases, sponsors can also leverage the comparative analytical assessment generated during the original 351(k) application rather than repeating a complete head-to-head exercise against new reference product lots.The broader takeaway is that FDA’s biosimilar framework has matured significantly. The pathway is not built around simply copying the innovator product forever. It is increasingly a lifecycle framework that gives sponsors meaningful flexibility while preserving strict boundaries around biosimilarity, product design, manufacturing comparability, and patient safety.FDA Sources:Questions and Answers on Biosimilar Development and the BPCI Act, Revision 4:https://www.fda.gov/media/119258/downloadPostapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Q&As:https://www.fda.gov/media/180206/downloadDisclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on PIC/S Recommendation PI 006-4, which entered into force on October 1, 2026, and what it means for qualification and validation across pharmaceutical manufacturing. The revised recommendation supersedes PI 006-3 and reinforces a lifecycle, risk-based approach aligned with modern GMP expectations.The central message is clear: validation is no longer a one-time event. PI 006-4 reinforces a lifecycle model built around Quality Risk Management, data governance, ongoing verification, and disciplined change control. The goal is not simply to demonstrate that a process or system worked during an initial qualification exercise, but to prove that it remains in a state of control throughout its operational life.The episode explores the full qualification lifecycle, from User Requirements Specification and Design Qualification through FAT, SAT, IQ, OQ, PQ, and periodic review. It also highlights the increasing acceptance of science- and engineering-based approaches such as ASTM E2500, provided the manufacturer can demonstrate that systems are fit for intended use.Process validation receives particular attention. The old shorthand of “three consecutive batches” is no longer enough by itself. PIC/S emphasizes that the number of validation batches should be scientifically justified based on process understanding, risk, variability, and prior knowledge. Traditional validation, Continuous Process Verification, and hybrid approaches may all be appropriate depending on the maturity of the process and the available control strategy.The guidance is equally clear on what is no longer acceptable. Retrospective validation is explicitly rejected. Legacy processes must instead be supported through gap assessment, ongoing process verification, requalification where necessary, and evidence that the process remains capable and controlled.Cleaning validation also moves firmly into a toxicology- and risk-based model. Health-Based Exposure Limits should drive Maximum Allowable Carry-Over limits, and low-HBEL products may require automated cleaning, dedicated equipment, or routine analytical verification rather than reliance on highly variable manual cleaning alone. The broader principle is that cleaning must be demonstrated to be reproducible, not simply “tested until clean.”The episode also examines several operational areas that often receive less attention but carry real compliance risk: transport verification, utility qualification, packaging validation, test method suitability, and the control of direct and indirect product-contact systems. These expectations reinforce that validation extends far beyond manufacturing equipment alone.The takeaway is that PI 006-4 pushes industry toward a more mature definition of validation: not a protocol, not a binder, and not a fixed number of batches, but a continuous operating discipline. The firms that adapt best will be those that integrate QRM, process knowledge, statistical monitoring, change management, and lifecycle verification into the way manufacturing actually operates.PIC/S Source:Revision of PIC/S Recommendations on Qualification and Validation (PI 006-4)PIC/S PI 006-4 publication noticeDisclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on what 30 FDA Human Drug and Biologic GMP Warning Letters issued through September 9, 2026 reveal about the Agency’s evolving enforcement strategy.The data show that FDA enforcement is becoming faster, broader, and less dependent on traditional on-site inspections. The median time from inspection close or records request to Warning Letter issuance was 176 days, but for many international facilities the Warning Letter was not the first consequence. Import Alert 66-40 frequently came first, meaning commercial impact often began weeks before the formal letter was issued.One of the clearest shifts is FDA’s expanded use of Section 704(a)(4) records requests. Several prescription and API manufacturers received Warning Letters based largely on remote document reviews, with FDA identifying serious deficiencies including missing process validation, absent stability programs, unvalidated analytical methods, and even data integrity manipulation without an investigator ever entering the facility.The underlying GMP failures, however, remain strikingly familiar. Inadequate investigations and Quality Unit oversight were each present in half of the letters analyzed. Sterility assurance, equipment and facility condition, cleaning validation, laboratory controls, stability, and data integrity continued to drive enforcement. Data integrity concerns have also evolved beyond simple backdating into more sophisticated forms of electronic manipulation involving trial injections, edited spectra, overwritten LIMS data, and software changes without audit trails.The analysis also shows that prior regulatory history is no guarantee of protection. Nearly one-quarter of the sites had never been inspected by FDA before the triggering action, yet several moved directly into OAI status, Import Alert, and Warning Letter territory. At the other end of the spectrum, some chronically poor-performing facilities continued to demonstrate repeat failures over multiple inspection cycles.International manufacturers face an especially challenging environment. Within this cohort, facilities in India and China received Warning Letters at substantially higher rates relative to closed FDA GMP inspections than U.S. facilities. The analysis also identified cases where active EU GMP documentation or positive European inspection outcomes did not prevent FDA from reaching an OAI conclusion and issuing a Warning Letter.The takeaway is that FDA’s enforcement model is becoming more continuous and intelligence-driven. Firms can no longer assume that the real regulatory risk begins when an investigator arrives on site—or even when a Warning Letter is posted. Import alerts, remote records reviews, supplier-chain tracing, and historical quality signals can all trigger consequences earlier.For industry, the message is straightforward: weak investigations, poor Quality Unit oversight, unresolved data integrity vulnerabilities, and fragile sterile manufacturing controls remain among the fastest ways to turn routine regulatory scrutiny into significant commercial risk.https://www.redica.com/resources/report/report---fda-warning-letters-to-human-drug-biologic-gmp-manufacturersSponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion turns to FDA’s intensifying scrutiny of compounded GLP-1 medications and what the September 2026 Empower Pharmacy Warning Letter may signal for the broader compounding industry.During the semaglutide and tirzepatide shortages, compounding filled an important supply gap. But with those shortages resolved, FDA is applying much greater scrutiny to whether compounded products meet the statutory conditions of section 503A. At the center of the issue is a deceptively simple question: when does a customized formulation represent a legitimate patient-specific need, and when is it merely an “essentially identical” copy of an FDA-approved drug?The Empower case highlights that adding ingredients such as cyanocobalamin or niacinamide does not automatically establish a clinically significant difference. FDA focused on whether prescribers actually documented an individualized need for the modified formulation and whether repeated, standardized rationales across large numbers of prescriptions reflected genuine clinical judgment or something closer to mass production.That brings telehealth and automated prescribing workflows directly into the compliance discussion. Pre-populated checkboxes, required fields, and standardized “significant difference” language may improve workflow efficiency, but they can also undermine the individualized prescribing foundation on which section 503A relies. High production volumes combined with repeated identical justifications may become powerful compliance signals for FDA investigators.The episode also examines what happens when a compounder falls outside the conditions of section 503A. The consequences can move quickly beyond documentation deficiencies. Products may lose statutory exemptions and become subject to requirements involving approved applications, labeling, and CGMP. In the Empower case, FDA’s concerns also extended into aseptic processing, media fills, smoke studies, environmental monitoring, Quality Unit oversight, and data integrity.And the patient-safety issue goes beyond the manufacturing suite. Compounded GLP-1 products supplied in multidose vials can introduce dosing complexity that does not exist with many commercial pen products. Confusion between milligrams, milliliters, concentrations, and syringe “units” has contributed to significant dosing errors, reinforcing why labeling, formulation, dispensing, and patient instructions are all part of the risk equation.The takeaway is that the shortage-era environment is ending. For compounders, telehealth providers, and prescribers, GLP-1 compliance is increasingly about demonstrating that customization is genuinely patient-specific, clinically meaningful, and supported by defensible records. Adding a vitamin, checking a box, or repeating a standardized rationale is unlikely to substitute for individualized clinical judgment.FDA Warning Letter: Empower Clinic Services, LLC dba Empower Pharmacy, Warning Letter No. 738238, issued September 18, 2026:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion takes a closer look at first-cycle Complete Response rates for CDER New Drug Applications and Biologics License Applications from FY 2008 through FY 2024.Recent industry commentary has suggested that Complete Response rates are structurally increasing. FDA’s own longitudinal analysis paints a more nuanced picture. The first-cycle CR rate for original NDAs and BLAs declined from approximately 47% in FY 2008 to about 27% in FY 2024. After a significant downward shift around FY 2011, rates largely stabilized around the 30% range rather than continuing on a sustained upward trajectory. (U.S. Food and Drug Administration⁠)The episode also explores why methodology matters when discussing approval statistics. Product-level approval data and submission-level PDUFA data are not interchangeable, and receipt cohorts can take multiple fiscal years to mature. Depending on the denominator, time period, and unit of analysis selected, very different narratives can emerge from what appears to be the same regulatory dataset.One of the most important findings is that a first-cycle Complete Response is not the same as ultimate failure. Across the period analyzed, the median first-cycle approval rate was approximately 64%, while roughly 77% of those original NDA and BLA applications are now in approved status after subsequent review cycles. (U.S. Food and Drug Administration⁠)The takeaway is that year-to-year fluctuations can generate headlines, but long-term data provide a better view of regulatory performance. The FDA analysis suggests that Complete Response rates are not on a persistent upward path and that many applications receiving an initial CR ultimately reach approval after deficiencies are addressed.For industry, the more useful question may not be whether CR rates are rising, but what separates applications that achieve first-cycle approval from those that require another round of review.Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.Source:FDA Report: First-Cycle Complete Response Rates for CDER NDA and BLA Applications: A Longitudinal Analysis, FY 2008–2024https://www.fda.gov/media/194858/download

On this episode of The Regulatory Mix, we examine the growing intersection of artificial intelligence, pharmaceutical manufacturing, and regulatory accountability. As AI moves deeper into Current Good Manufacturing Practice environments, the key question is not whether firms will use it, but whether they can do so without weakening quality oversight, critical thinking, and compliance discipline.A recent FDA Warning Letter to Purolea Cosmetics Lab provides a clear example of what can go wrong when AI is used without meaningful human review. The firm relied on AI to generate product specifications, procedures, and production records, while basic CGMP responsibilities were not adequately understood or controlled. FDA specifically criticized the lack of Quality Unit oversight and the firm’s failure to recognize process validation requirements.The episode also looks at FDA’s emerging risk-based framework for evaluating AI credibility. The level of assurance required depends on three key factors: the model’s context of use, how much influence it has on a decision, and the consequence if that decision is wrong. The greater the model’s role and the higher the patient or product risk, the stronger the expectation for validation and oversight.Beyond compliance, the discussion turns to the effect of generative AI on human judgment. Research involving knowledge workers suggests that AI can shift cognitive effort away from direct problem-solving and toward verification and supervision. That can improve efficiency, but it also creates risks such as automation bias, reduced independent thinking, and skill atrophy when users become overly dependent on machine-generated outputs.The takeaway is simple: AI can assist regulated work, but it cannot assume regulatory responsibility. Accountability remains with the firm, the Quality Unit, and the qualified individuals responsible for ensuring that every decision affecting product quality and patient safety is scientifically sound and compliant.Reference Links:Purolea Cosmetics Lab Warning Letter:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026FDA Draft Guidance on AI Model Credibility:https://www.fda.gov/media/184830/downloadResearch: AI and Critical Thinkinghttps://www.microsoft.com/en-us/research/wp-content/uploads/2025/01/lee_2025_ai_critical_thinking_survey.pdfSponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.Disclaimer:The views expressed in this episode are personal opinions for educational purposes only and do not constitute legal, regulatory, or medical advice.